Those French researchers killed a patient and injured 5 others by using high doses instead of being slow and cautious like CTIX. I agree with you and am glad that CTIX is being cautious with dosing. If it weren't for Menon's genius in recognizing that the problem with Brilacidin when PolyMedix tested it was that they were using doses that were grossly too high, we wouldn't have the whole Brilacidin platform which IMO is going to be the most important drug in the pipeline.